FK614 - 半岛电竞官方网址

立即咨询

咨询类型：

采购售后

*姓名：

*电话：

*单位：

Email：

*留言内容：

请详细说明您的需求。

*验证码：

FK614

本半岛bd体育手机客户端不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

193012-35-0

包装与价格：

包装	价格(元)
5mg	电议
10mg	电议

半岛bd体育手机客户端介绍

FK614 是一种具有口服活性，有效的，选择性的 PPARγ 调制剂 (SPPARM)。FK614 对脂肪细胞分化各阶段 PPARγ 的激活有不同的影响。FK614 是一种非噻唑烷二酮类胰岛素增敏剂。FK614 可用于高血糖、高甘油三酯、葡萄糖耐受不良和 2 型糖尿病的研究。

Cas No.	193012-35-0
分子式	C₂₁H₂₃Cl₂N₃O₃S
分子量	468.4
溶解度	DMSO : 100 mg/mL (213.49 mM; Need ultrasonic)
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
半岛bd体育手机客户端描述	FK614 is an orally active, potent, selective PPARγ modulator (SPPARM). FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is a nonthiazolidinedione insulin sensitizer. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes[1][2][3]. FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia[1][2]. FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level[3].FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance[3]. [1]. Fujimura T, et al. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties. J Pharmacol Exp Ther. 2006;318(2):863-871. [2]. Fujimura T, et al. FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. J Pharmacol Sci. 2005;99(4):342-352.